DE69826841D1 - Phthalazines mit angiogenesis-hemmender wirkung - Google Patents

Phthalazines mit angiogenesis-hemmender wirkung

Info

Publication number
DE69826841D1
DE69826841D1 DE69826841T DE69826841T DE69826841D1 DE 69826841 D1 DE69826841 D1 DE 69826841D1 DE 69826841 T DE69826841 T DE 69826841T DE 69826841 T DE69826841 T DE 69826841T DE 69826841 D1 DE69826841 D1 DE 69826841D1
Authority
DE
Germany
Prior art keywords
phthalazines
inhibiting effect
angiogenesis inhibiting
angiogenesis
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826841T
Other languages
English (en)
Other versions
DE69826841T2 (de
Inventor
Guido Bold
Joerg Frei
Peter Traxler
Karl-Heinz Altmann
Helmut Mett
Raymond Stover
Jeanette Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Application granted granted Critical
Publication of DE69826841D1 publication Critical patent/DE69826841D1/de
Publication of DE69826841T2 publication Critical patent/DE69826841T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69826841T 1997-02-13 1998-02-11 Phthalazines mit angiogenesis-hemmender wirkung Expired - Lifetime DE69826841T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH31597 1997-02-13
CH31597 1997-02-13
PCT/EP1998/000764 WO1998035958A1 (en) 1997-02-13 1998-02-11 Phthalazines with angiogenesis inhibiting activity

Publications (2)

Publication Number Publication Date
DE69826841D1 true DE69826841D1 (de) 2004-11-11
DE69826841T2 DE69826841T2 (de) 2006-02-09

Family

ID=4184213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826841T Expired - Lifetime DE69826841T2 (de) 1997-02-13 1998-02-11 Phthalazines mit angiogenesis-hemmender wirkung

Country Status (32)

Country Link
US (3) US6258812B1 (de)
EP (1) EP0970070B1 (de)
JP (1) JP3544675B2 (de)
KR (1) KR100441362B1 (de)
CN (1) CN1251097B (de)
AR (1) AR011135A1 (de)
AT (1) ATE278686T1 (de)
AU (1) AU731852B2 (de)
BR (1) BR9807685B1 (de)
CA (1) CA2281721C (de)
CO (1) CO4950519A1 (de)
CY (1) CY2550B1 (de)
CZ (1) CZ297534B6 (de)
DE (1) DE69826841T2 (de)
DK (1) DK0970070T3 (de)
ES (1) ES2234097T3 (de)
HU (1) HU227972B1 (de)
ID (1) ID23698A (de)
IL (1) IL131273A0 (de)
MY (1) MY128645A (de)
NO (1) NO317367B1 (de)
NZ (1) NZ337064A (de)
PE (1) PE52499A1 (de)
PL (1) PL197371B1 (de)
PT (1) PT970070E (de)
RU (1) RU2207132C2 (de)
SI (1) SI0970070T1 (de)
SK (1) SK285757B6 (de)
TR (1) TR199901953T2 (de)
TW (1) TWI250151B (de)
WO (1) WO1998035958A1 (de)
ZA (1) ZA981155B (de)

Families Citing this family (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1005470B1 (de) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylchinazolinderivate als angiogenesehemmer
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
ATE371453T1 (de) * 1998-08-13 2007-09-15 Novartis Pharma Gmbh Verfahren zur behandlung von okularen neovaskularen erkrankungen
AU766081B2 (en) * 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
ATE295365T1 (de) * 2000-02-09 2005-05-15 Novartis Pharma Gmbh Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
EP1166798A1 (de) * 2000-06-23 2002-01-02 Schering Aktiengesellschaft Zusammensetzungen die interferieren mit VEGF/VEGF und Angiopoietin/Tie Rezeptor-Funktionen
KR20030036238A (ko) * 2000-06-23 2003-05-09 쉐링 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
EP1166799A1 (de) * 2000-06-28 2002-01-02 Schering Aktiengesellschaft Zusammensetzungen die interferieren mit VEGF/VEGF und Angiopoietin/Tie Rezeptor-Funktionen
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6903101B1 (en) * 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
BR0115062A (pt) * 2000-10-30 2004-02-17 Kudos Pharm Ltd Derivados de ftalazinona
CA2427184A1 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
US7814641B2 (en) * 2001-01-09 2010-10-19 Black & Decker Inc. Method of forming a power tool
US7096566B2 (en) * 2001-01-09 2006-08-29 Black & Decker Inc. Method for making an encapsulated coil structure
EP1363627A2 (de) 2001-02-19 2003-11-26 Novartis AG Behandlung von festen tumoren mit rapamycin derivaten
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
CN1700917B (zh) 2001-05-16 2010-04-28 诺瓦提斯公司 含n-(5-{4-[4-甲基-(1-哌嗪基)甲基]-苯甲酰氨基}-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶-胺和化疗药的联合形式
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
DK1427420T3 (da) * 2001-09-12 2006-10-02 Novartis Ag Anvendelse af en kombination indeholdende 4-pyridylmethyl-phthalaziner til cancerbehandling
SI1427420T1 (sl) * 2001-09-12 2006-12-31 Novartis Ag Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
WO2003028711A2 (en) * 2001-09-27 2003-04-10 Novartis Ag Use of c-kit inhibitors for the treatment of myeloma
BR0213486A (pt) * 2001-10-25 2005-05-10 Novartis Ag Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
CA2470480C (en) * 2001-12-27 2010-12-14 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003233198A1 (en) * 2002-04-30 2003-11-17 Novartis Ag Method for decreasing capillary permeability in the retina
DK1505959T3 (da) * 2002-05-16 2009-02-23 Novartis Ag Anvendelse af EDG-receptorbindingsmidler ved cancer
US7754716B2 (en) * 2002-06-28 2010-07-13 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
AU2003299065B2 (en) * 2002-09-24 2006-10-26 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EP1554015A1 (de) * 2002-10-10 2005-07-20 Novartis AG Behandlung von amm
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
EP1562591A1 (de) * 2002-11-12 2005-08-17 Novartis AG Behandlung von mesotheliomen
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
EP1581228A1 (de) * 2002-12-20 2005-10-05 Dana-Farber Cancer Institute, Inc. Behandlung der von-hippel-lindau krankheit
EP1641458A2 (de) * 2002-12-27 2006-04-05 Schering Aktiengesellschaft Pharmazeutische zusammensetzungen aus phthalazine vegf hemmern und benzamide hdac hemmern
EP1602647B1 (de) 2003-03-07 2013-10-16 Santen Pharmaceutical Co., Ltd. Neue verbindungen mit 4-pyridylalkylthiogruppe als substituent
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
WO2005017107A2 (en) 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor
EP1683785B1 (de) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Harnstoffderivate und verfahren zu deren herstellung
CN1882344A (zh) 2003-11-18 2006-12-20 诺瓦提斯公司 Kit突变形式的抑制剂
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2005085201A1 (ja) 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
EP1568368A1 (de) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmazeutische Kombination enthaltend einen CDK Inhibitoren und einen VEGF Rezeptor Inhibitoren
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (de) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Gemeinsame Verwendung einer sulfonamidbasierten Verbindung mit Angiogenesehemmer
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
AU2005312048B2 (en) 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
EP1854787B1 (de) * 2005-03-03 2010-09-01 Santen Pharmaceutical Co., Ltd. Neue cyclische verbindung mit chinolylalkylthiogruppe
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US7906511B2 (en) 2005-03-31 2011-03-15 Santen Pharmaceutical Co., Ltd. Cyclic compound having pyrimidinylalkylthio group
GT200600147A (es) * 2005-04-13 2006-11-24 Uso de inhibidores de receptor de factor de crecimiento endotelial vascular para el tratamiento de canceres gastrointestinal, genitourinario, linfoide y pulmonar
JP5129123B2 (ja) 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1731154A1 (de) 2005-06-07 2006-12-13 Schering Aktiengesellschaft Pharmazeutische Formulierungen mit sofortiger Freisetzung und hohem Wirkstoffanteil von micronisiertem (4-Chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| und dessen Salzen
EP1731153A1 (de) * 2005-06-07 2006-12-13 Schering Aktiengesellschaft Pharmazeutische Formulierungen mit sofortiger Freisetzung und hohem Wirkstoffanteil von nicht micronisiertem (4-Chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| und dessen Salzen
EP2281901B1 (de) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Pharmazeutische anti-tumor Zusammensetzung mit Angiogeneseinhibitoren
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CN101277939A (zh) * 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ES2353482T3 (es) 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US20090098137A1 (en) 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8777120B2 (en) * 2006-04-15 2014-07-15 International Business Machines Corporation Hydronic radiant flooring heating system
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2021338A1 (de) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylaminosäurederivate und pharmazeutische zusammensetzung davon
CA2649792A1 (en) 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
MX2009001349A (es) 2006-08-04 2009-04-17 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
WO2008093677A1 (ja) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
CN101116664B (zh) * 2007-08-28 2010-05-19 山东省科学院生物研究所 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
ES2519474T3 (es) 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN103816158A (zh) 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
US20110223241A1 (en) 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
WO2010071794A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
RU2011129229A (ru) 2008-12-18 2013-01-27 Новартис Аг Новые соли
DK2379497T3 (da) 2008-12-18 2013-11-25 Novartis Ag Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
BRPI1013639A2 (pt) 2009-02-13 2016-04-19 Boehringer Ingelheim Int medicamentos antidiabéticos
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EA021011B1 (ru) 2009-06-26 2015-03-31 Новартис Аг 1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (de) 2009-08-12 2012-06-20 Novartis AG Heterocyclische hydrazonverbindungen und ihre verwendung zur behandlung von krebs und entzündung
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
MX2012002420A (es) 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
JP2013504543A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 二環ヘテロアリール類のエーテル誘導体
MX370429B (es) 2009-10-02 2019-12-13 Boehringer Ingelheim Int Gmbh Star Composiciones farmacéuticas que comprenden bi-1356 y metformina.
WO2011054828A1 (en) 2009-11-04 2011-05-12 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
SG186983A1 (en) 2010-07-09 2013-02-28 Genentech Inc Anti-neuropilin antibodies and methods of use
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP2627648A1 (de) 2010-09-16 2013-08-21 Novartis AG 17a-HYDROXYLASE-C17, 20-LYASE-INHIBITOREN
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
CA2817564A1 (en) 2010-11-18 2012-05-24 Ronald K. Blackman Preselection of subjects for therapeutic treatment based on hypoxic status
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EP2683722A1 (de) 2011-03-08 2014-01-15 Novartis AG Bicyclische fluorphenyl-heteroarylverbindungen
CA2830516C (en) 2011-03-23 2017-01-24 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EP2700403B1 (de) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutikum für tumor
KR20140025492A (ko) 2011-04-28 2014-03-04 노파르티스 아게 17α-히드록실라제/C17,20-리아제 억제제
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2718276A1 (de) 2011-06-09 2014-04-16 Novartis AG Heterocyclische sulfonamidderivate
BR112013032273B1 (pt) * 2011-06-16 2020-11-17 Korea Research Institute Of Chemical Technology Compostos derivados de 1,3-dioxoindeno, seus usos, métodos de preparação dos mesmos e composições farmacêutica
EP2721008B1 (de) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituierte isochinolinone als p53 (mdm2 or mdm4) inhibitoren
EP2721007B1 (de) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl-isochinolinon-verbindungen
EP2731947B1 (de) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
WO2013096049A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794592A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
BR112014015442A8 (pt) 2011-12-23 2017-07-04 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
EP4151218A1 (de) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
BR112014028420A2 (pt) 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
EP2890696A1 (de) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinonverbindungen und derivate davon
WO2014092514A1 (ko) 2012-12-14 2014-06-19 한국화학연구원 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
KR20150128726A (ko) 2013-03-15 2015-11-18 베링거 인겔하임 인터내셔날 게엠베하 심장보호 및 신장보호 항당뇨병 치료요법에서의 리나글립틴의 사용
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JP2016539149A (ja) 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
CN107517589A (zh) 2015-01-08 2017-12-26 小利兰·斯坦福大学托管委员会 提供骨、骨髓及软骨的诱导的因子和细胞
US20180093956A1 (en) * 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
EP3507367A4 (de) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
HUE056777T2 (hu) 2016-12-22 2022-03-28 Amgen Inc Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
US20210128615A1 (en) 2017-10-18 2021-05-06 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886A1 (de) 2018-05-10 2021-03-17 Amgen Inc. Kras-g12c-hemmer zur behandlung von krebs
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP2021530508A (ja) 2018-07-17 2021-11-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓および腎臓に安全な抗糖尿病療法
BR112020024793A2 (pt) 2018-07-17 2021-03-02 Boehringer Ingelheim International Gmbh terapia antidiabética cardiossegura
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3123042A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
EP3898616A1 (de) 2018-12-20 2021-10-27 Amgen Inc. Als kif18a-inhibitoren verwendbare heteroarylamide
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
AU2020274186A1 (en) 2019-05-14 2021-12-09 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
JP2022542967A (ja) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
JP2023500328A (ja) 2019-11-08 2023-01-05 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
AU2022212106A1 (en) * 2021-01-28 2023-08-17 University Of Florida Research Foundation, Incorporated Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
JP2024517847A (ja) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
EP4358963A1 (de) * 2021-06-21 2024-05-01 Mirati Therapeutics, Inc. Sos1-inhibitoren
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023121413A1 (ko) * 2021-12-24 2023-06-29 제일약품주식회사 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (de) * 1957-05-07
US2960504A (en) 1957-05-07 1960-11-15 Ciba Pharm Prod Inc 1-hydrazino, 4-pyridyl methyl-phthalazines
GB1094044A (en) 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
DE1695994A1 (de) 1967-05-05 1971-05-19 Vantorex Ltd Verfahren zur Herstellung von Phthalazinen
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
ES2224130T3 (es) * 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
NZ326354A (en) * 1996-01-15 1999-05-28 Janssen Pharmaceutica Nv 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments
DE19617863A1 (de) 1996-04-23 1997-10-30 Schering Ag Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ATE371453T1 (de) * 1998-08-13 2007-09-15 Novartis Pharma Gmbh Verfahren zur behandlung von okularen neovaskularen erkrankungen

Also Published As

Publication number Publication date
AR011135A1 (es) 2000-08-02
US6514974B2 (en) 2003-02-04
PT970070E (pt) 2005-02-28
RU2207132C2 (ru) 2003-06-27
CN1251097A (zh) 2000-04-19
ATE278686T1 (de) 2004-10-15
ZA981155B (en) 1998-08-13
CY2550B1 (de) 2008-07-02
ES2234097T3 (es) 2005-06-16
SK109699A3 (en) 2000-03-13
CN1251097B (zh) 2011-10-19
CA2281721C (en) 2008-01-22
KR100441362B1 (ko) 2004-07-23
ID23698A (id) 2000-05-11
CA2281721A1 (en) 1998-08-20
BR9807685A (pt) 2000-03-21
CZ285399A3 (cs) 1999-11-17
TWI250151B (en) 2006-03-01
EP0970070B1 (de) 2004-10-06
PE52499A1 (es) 1999-06-10
SI0970070T1 (en) 2005-04-30
US6258812B1 (en) 2001-07-10
NZ337064A (en) 2001-04-27
IL131273A0 (en) 2001-01-28
BR9807685B1 (pt) 2013-05-21
CO4950519A1 (es) 2000-09-01
PL197371B1 (pl) 2008-03-31
DK0970070T3 (da) 2005-02-14
NO317367B1 (no) 2004-10-18
MY128645A (en) 2007-02-28
EP0970070A1 (de) 2000-01-12
TR199901953T2 (xx) 1999-10-21
HU227972B1 (en) 2012-07-30
NO993888L (no) 1999-10-11
NO993888D0 (no) 1999-08-12
US6710047B2 (en) 2004-03-23
JP2001508800A (ja) 2001-07-03
CZ297534B6 (cs) 2007-01-03
HUP0001046A2 (hu) 2001-04-28
DE69826841T2 (de) 2006-02-09
US20020091261A1 (en) 2002-07-11
PL335113A1 (en) 2000-04-10
WO1998035958A1 (en) 1998-08-20
KR20000071049A (ko) 2000-11-25
US20030191129A1 (en) 2003-10-09
HUP0001046A3 (en) 2002-04-29
JP3544675B2 (ja) 2004-07-21
AU6621898A (en) 1998-09-08
SK285757B6 (sk) 2007-07-06
AU731852B2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
DE69937668D1 (de) Elektrolumineszentes element
EE200000291A (et) 2-fenüülasendatud imidasotriasinoonid
DK0966430T3 (da) Anti-flammatoriske forbindelser
DE69827870D1 (de) Drebohrmeissel mit beweglichen Formation-eingreifenden Elementen
DE69836513D1 (de) Thermooptische Vorrichtungen
NO963261L (no) Löpehjul
DE69812236T2 (de) Schutzbekleidung
DE69506520D1 (de) Geschützter schalter
DE69518972D1 (de) Geschützter schalter
DE69836069D1 (de) Zweirichtungsthyristor
DE59905139D1 (de) Strukturelement
ATA190197A (de) Rolladen-vorbauelement
DE29608321U1 (de) Markierungselement
DE69810575T2 (de) Elektrolumineszentes Element
DE59712400D1 (de) Brennerelement
DE29713226U1 (de) Drainageelement
ATA190297A (de) Rolladen-vorbauelement
DE69827935D1 (de) Antennenelement
DE69809296D1 (de) Mehrzonenelement
DE19726486B4 (de) Schaltelement
NO992383D0 (no) Beskyttelsesklesplagg
DE29614257U1 (de) Lateralelement
DE29603623U1 (de) Hochwasserschutzelement
DE29712457U1 (de) Rollrasen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN